Literature DB >> 16177953

Barrett's oesophagus is characterized by a predominantly humoral inflammatory response.

Leon M G Moons1, Johannes G Kusters, Evelien Bultman, Ernst J Kuipers, Herman van Dekken, Wendy M W Tra, Alex Kleinjan, Jaap Kwekkeboom, Arnoud H M van Vliet, Peter D Siersema.   

Abstract

Barrett's oesophagus (BO) is thought to be an intermediate step in the progression from reflux oesophagitis (RO) to oesophageal adenocarcinoma. Premalignant conditions that develop in the presence of chronic inflammation are often associated with the development of a more pronounced humoral immune response during progression of the disease. The aim of this study was to determine whether BO is also associated with a more pronounced humoral immune response when compared to RO. Immunohistochemical studies were performed to quantify the mean numbers of Th2 effector cells (plasma cells and mast cells) and Th1 effector cells (macrophages and CD8(+) T cells) to detect the antibody classes produced by plasma cells (IgA, IgG, IgM or IgE) and to determine the presence of isolated lymph follicles [segregated B and T cell areas, follicular dendritic cells (CD23) and expression of CXCL13] in 124 oesophageal biopsies from 20 patients with BO and 20 patients with RO. The proportion of Th2 effector cells was higher in BO than in RO, mainly due to higher numbers of plasma cells and mast cells in BO (p < 0.001). Most plasma cells in BO and RO expressed IgG, but several IgE(+) plasma cells were detected in BO: these were rare in RO. In line with this, isolated lymph follicles were observed in 4/20 (20%) patients with BO, but not in RO. We therefore conclude that the inflammatory response is skewed towards a more pronounced humoral immune response when RO progresses to BO. It may be that this shift, which is similar to that found in other chronic inflammatory conditions, contributes to an increased cancer risk in BO. Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177953     DOI: 10.1002/path.1847

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

Review 1.  Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia.

Authors:  Douglas B Stairs; Jianping Kong; John P Lynch
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress.

Authors:  Jianping Kong; Kelly A Whelan; Dorottya Laczkó; Brendan Dang; Angeliz Caro Monroig; Ali Soroush; John Falcone; Ravi K Amaravadi; Anil K Rustgi; Gregory G Ginsberg; Gary W Falk; Hiroshi Nakagawa; John P Lynch
Journal:  Mol Carcinog       Date:  2015-09-16       Impact factor: 4.784

Review 3.  Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

Authors:  Florian Rieder; Piero Biancani; Karen Harnett; Lisa Yerian; Gary W Falk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-18       Impact factor: 4.052

Review 4.  Vitamin D and the epidemiology of upper gastrointestinal cancers: a critical analysis of the current evidence.

Authors:  Ryan Trowbridge; Sumeet K Mittal; Devendra K Agrawal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-05       Impact factor: 4.254

Review 5.  The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.

Authors:  Zhaohui Jin; Harry H Yoon
Journal:  J Gastrointest Oncol       Date:  2016-10

6.  Serotonin disrupts esophageal mucosal integrity: an investigation using a stratified squamous epithelial model.

Authors:  Liping Wu; Tadayuki Oshima; Toshihiko Tomita; Yoshio Ohda; Hirokazu Fukui; Jiro Watari; Hiroto Miwa
Journal:  J Gastroenterol       Date:  2016-03-16       Impact factor: 7.527

7.  Rebamipide Alters the Esophageal Microbiome and Reduces the Incidence of Barrett's Esophagus in a Rat Model.

Authors:  Yukie Kohata; Kenichi Nakahara; Tetsuya Tanigawa; Hirokazu Yamagami; Masatsugu Shiba; Toshio Watanabe; Kazunari Tominaga; Yasuhiro Fujiwara; Tetsuo Arakawa
Journal:  Dig Dis Sci       Date:  2015-04-11       Impact factor: 3.199

8.  Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.

Authors:  Brooke M Winzer; Jennifer D Paratz; Marina M Reeves; David C Whiteman
Journal:  BMC Cancer       Date:  2010-06-16       Impact factor: 4.430

Review 9.  Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin.

Authors:  Jing Li; Xiaoxin Luke Chen; Anisa Shaker; Tadayuki Oshima; Jing Shan; Hiroto Miwa; Cheng Feng; Jun Zhang
Journal:  Ann N Y Acad Sci       Date:  2016-07-21       Impact factor: 5.691

10.  Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Yuri V Bobryshev; Dinh Tran; Murray C Killingsworth; Michael Buckland; Reginald V N Lord
Journal:  J Gastrointest Surg       Date:  2008-08-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.